Genprex granted U.S. patenet for Reqorsa Gene Therapy in cancer

Genprex (GNPX) announced that the USPTO has granted Genprex a patent that covers the use of the company’s lead drug candidate, Reqorsa Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq, through 2037. Genprex has been granted patents for the use of REQORSA in combination with PD-L1 antibodies in the U.S. and Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China and Israel.